# Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease

> **NCT07280702** · PHASE4 · NOT_YET_RECRUITING · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 128 (estimated)

## Conditions studied

- Psoriatic Arthritis (PsA)

## Interventions

- **DRUG:** Deucravacitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07280702
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-15
- **Primary completion:** 2027-12-15
- **Final completion:** 2027-12-15
- **Target enrollment:** 128 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07280702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07280702, "Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07280702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*